[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 5, 1994

Efficacy of Divalproex vs Lithium and Placebo in Mania

Author Affiliations

Rush-Presbyterian-St Luke's Medical Center Chicago, Ill

JAMA. 1994;272(13):1005-1006. doi:10.1001/jama.1994.03520130039027

To the Editor.  —We read with interest the report by Dr Bowden and colleagues1 on the effectiveness of divalproex sodium compared with lithium and placebo for hospitalized, acutely manic patients. We, too, have observed the therapeutic benefits of this anticonvulsant for refractory bipolar and schizoaffective patients who failed previous trials with lithium and/or carbamazepine.2However, we would like to comment on methodological issues that may bear on the interpretation of their findings. First, the lithium group comprised a large group of prior treatment failures; 86% (n=31) of this group had received lithium in the past, and 48% reported ineffectiveness or intolerance. Thus, lithium may be serving as an active placebo rather than as a pharmacologic treatment for many in this group. Furthermore, the lithium group was only half as large as either the placebo group or the divalproex group. Although Bowden et al correctly observe that this smaller

First Page Preview View Large
First page PDF preview
First page PDF preview